Bryan K. Yip

Delivery of an enzyme-IGFII fusion protein to the mouse brain is therapeutic for mucopolysaccharidosis type IIIB

Shih‐hsin Kan, Mika Aoyagi-Scharber, Steven Q. Le et al. · Proceedings of the National Academy of Sciences · 2014 · 117 citations · Full text

Genetic ablation of acid ceramidase in Krabbe disease confirms the psychosine hypothesis and identifies a new therapeutic target

Yedda Li, Yue Xu, Bruno A. Benítez et al. · Proceedings of the National Academy of Sciences · 2019 · 93 citations · Full text

Structural basis for the inhibition of poly(ADP-ribose) polymerases 1 and 2 by BMN 673, a potent inhibitor derived from dihydropyridophthalazinone

Mika Aoyagi-Scharber, A.S. Gardberg, Bryan K. Yip et al. · Acta Crystallographica Section F Structural Biology Communications · 2014 · 54 citations · Full text

Potent Inhibitor, Molecular Biology, Chemical Biology +17

Clearance of Heparan Sulfate and Attenuation of CNS Pathology by Intracerebroventricular BMN 250 in Sanfilippo Type B Mice

Mika Aoyagi-Scharber, Danielle Crippen-Harmon, Roger Lawrence et al. · Molecular Therapy — Methods & Clinical Development · 2017 · 37 citations · Full text

BMN 250, a fusion of lysosomal alpha-N-acetylglucosaminidase with IGF2, exhibits different patterns of cellular uptake into critical cell types of Sanfilippo syndrome B disease pathogenesis

Gouri Yogalingam, Amanda Luu, Heather Prill et al. · PLoS ONE · 2019 · 20 citations · Full text

Genetics, Immunology, Pathology +24